Summer 2019 newsletter to clinical teams 2019
Registry news for IBD teams – Summer 2019
- Zessly safety study opens for interest
- Webtool upgrade – down time 17th July
- BSG 2019 Glasgow – IBD Data and Quality
- Survey: why do you participate in the IBD Registry?
- IBD audit requirements Quality Accounts 2019-20
- WebTool Wizards
- Supporting studies
- New IBD Standards in focus
- IBD Consensus Guidelines
- Support packs coming…
- Registry poster— audit of biological therapies in IBD unveiled
- Patient consent congrats to IBD teams
- PMS User Group—update
Find out more about:
The IBD Registry is recruiting three important posts to help its next phase of growth as one of the largest IBD registries in Europe. We are recruiting a Data Analytics Manager, a Projects and Operations Manager and a Data Analyst/ Developer. The roles will support...
The IBD Registry has published its first Annual Report on the Use of Biologics for Inflammatory Bowel Diseases for the year 2018-19. The report includes the cumulative results to January 2019 from April 2016 when the Registry assumed the role of supporting the National Audit of Biological Therapies from the Royal College of Physicians.
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD). The IBD hub, to be known as Gut Reaction – The Health Data Research Hub for Inflammatory Bowel Disease, will bring together...
The IBD Registry is inviting UK IBD clinical centres to participate in a post-marketing safety study of patients using Zessly (infliximab), a biosimilar available for the treatment of Inflammatory Bowel Disease (IBD). This study is facilitated by the Registry on...
The IBD Registry is delighted a presentation prepared by the Registry’s Analytics Hub at the University of Liverpool featured in the British Society of Gastroenterology Annual Meeting in Glasgow. The Audit of biological therapy for IBD - Shawihdi et al Poster BSG 2019...